milatamab

Milatamab (likely a nomenclature error for **militamiR**) is an AI-driven microRNA (miRNA) therapeutic candidate being developed by **Pharmahungary Group**. The program is designed to target musculoskeletal conditions with the goal of increasing physical strength and endurance. Developed using the company's proprietary AI-driven miRNA discovery platform, the project is currently in the preclinical discovery stage (approximately 25% progress as of recent reports). While the specific molecular targets and mechanism of action have not been publicly disclosed, the therapeutic approach involves modulating miRNA pathways to enhance physical performance. The name 'milatamab' appears to be a misspelling or incorrect designation in the provided context, as the '-mab' suffix is reserved for monoclonal antibodies, whereas this candidate is a miRNA-based therapy.

Other names

militamiR